← All trials
NCT06196320
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2024
- Primary completion
- Feb 1, 2026
- Completion date
- May 1, 2026
- First posted
- Jan 9, 2024
- Last posted
- Jan 16, 2024
- Enrollment
- 452
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- University of MelbourneOfficial
- Capital Medical UniversitySponsor investigator
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.